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Sir,
We read with interest the article entitled ‘OPA1-related audi-
tory neuropathy: site of lesion and outcome of cochlear im-
plantation’ published by Santarelli and colleagues (2015).
Hearing loss is a recognized symptom of a number of mito-
chondrial diseases and can result from neuronal (auditory
nerve, brainstem, auditory cortex) or cochlear dysfunction.
Although there have been isolated reports of auditory neur-
opathy in patients with mitochondrial disease (Ceranic and
Luxon, 2004; Gamez and Minoves, 2006), Santarelli et al.
(2015) were the first to show that it is an important cause of
hearing impairment in a genetically defined subset of these
patients.
Santarelli et al. (2015) comprehensively investigated the
auditory phenotype in subjects with both missense (n = 10)
and haploinsufficiency (n = 11) mutations in OPA1, which
were first described in patients with autosomal dominant
optic atrophy (Alexander et al., 2000; Delettre et al., 2000).
Nine of eleven patients carrying haploinsufficiency variants
had normal hearing whereas 9 of 10 patients carrying mis-
sense variants had a hearing impairment consistent with an
auditory neuropathy. Cochlear implantation of six patients
carrying missense OPA1 mutations resulted in improved
speech perception in all but one. Their findings indicate that
the auditory neuropathy resulted from auditory nerve dysyn-
chrony, and cochlear implantation subsequently improved
auditory nerve synchrony and speech perception. This work
provides a significant insight into the mechanism of hearing
impairment and validates a treatment option in a cohort of
patients with a classical form of mitochondrial disease.
Mutations in OPA1 accounted for 3% of cases in a
well-characterized patient cohort with multi-systemic mito-
chondrial disease (Gorman et al., 2015). To determine
whether the same mechanism is causing hearing impair-
ment in other mitochondrial disorders, we studied four dif-
ferent genetically defined groups, including the most
common mitochondrial DNA (mtDNA) mutation asso-
ciated with deafness (m.3243A4G), and three nuclear
genetic mitochondrial disorders caused by mutations in:
POLG, SPG7, which is the most commonly diagnosed mu-
tation in this patient group, and OPA1 (Table 1). Our
study had the relevant ethical and NHS approval.
We undertook auditory phenotyping to interrogate both
cochlear and neuronal hearing function. Pure tone audiom-
etry at test frequencies of 0.25, 0.5, 1, 2, 4 and 8 kHz was
used to ascertain overall subjective hearing level as a test of
the whole auditory pathway. The pure-tone average, PTA,
was defined as the average threshold across all of these test
frequencies used. Neuronal function was tested with audi-
tory brainstem responses (ABRs). Here, a click stimulus
with alternating polarity was delivered at a suitable sensa-
tion level as to give a clear response. The sensation level
was predetermined by the mean hearing level by ear at
2/4 kHz:440 dB HL used click stimulus at 70 dB nHL,
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40–60 dB HL used click stimulus at 80 dB nHL,460 dB
HL used click stimulus at 90 dB nHL. Contralateral mask-
ing was applied when required.
On average, 2000 responses were obtained on each side
and these were bandpass filtered between 8 and 15Hz.
Waveforms and latencies of waves I–V were calculated and
compared against age-matched values. Where the I–V interval
was not available wave III–V and absolute V latency were
calculated. Cochlear function was specifically tested using
transient evoked otoacoustic emissions (TEOAEs) (click
stimulus 84dB SPL) for outer hair cell function and psychoa-
coustic tuning curves (PTCs) for both outer and inner hair
cell function. Measurement of PTCs is the gold standard test
for the detection of cochlear dead regions (Moore and
Alcantara, 2001; Kluk and Moore, 2005). These regions of
the cochlea, where the inner hair cells and/or auditory neu-
rons are non-functional, are defined by the characteristic fre-
quency of the auditory neurons adjacent to the affected
region. A tone producing peak vibration in a dead region
may be detected by ‘off frequency listening’, i.e. by spread
of basilar-membrane vibration to a place in the cochlea
where the inner hair cells/neurons are still functioning. The
PTC is the level of a narrowband masker that is required to
mask a sinusoidal signal measured as a function of the
masker frequency. For normal-hearing individuals the tip of
the PTC (the frequency at which the level of the masker is
lowest) lies at or close to the signal frequency, whereas when
the signal frequency falls in a dead region the PTC tip will be
shifted from the signal frequency. The detection of cochlear
dead regions may potentially elucidate hearing loss mechan-
isms. In conjunction with increased audiometric thresholds at
defined frequencies a dead region may indicate specific im-
pairment of inner hair cells. On the other hand, elevation of
audiometric thresholds over a wide frequency range com-
bined with broad PTCs without shifted tips is more likely
to be a consequence of global metabolic cochlear disturbance
resulting from dysfunction of the stria vascularis.
Using the ‘SWPTC’ programme, PTCs were measured
using signal frequencies of 1, 2 and 4 kHz (Sek et al.,
2005; Sek and Moore, 2011). The four point moving aver-
age (4-PMA) method, in conjunction with visual inspection,
was used to identify tip shifts away from the signal fre-
quency. A tip shift of 10% was taken as indicating a
dead region at the signal frequency (tip frequency: signal
frequency41.10/50.9), except when the PTC was very
broad, giving a poorly defined tip.
m.3243A4G patient group
Patients with the m.3243A4G mutation (n = 11) pre-
sented with a range of hearing levels: normal (n = 3/11);
mild-to-moderate high-frequency loss (n = 5/11, mean
PTA = 58dB HL, age-corrected PTA = 39dB HL); and
severe-to-profound loss at all measured frequencies (n = 3/
11, mean PTA = 91dB HL, age-corrected PTA = 61dB HL).
Patients with pathological mtDNA mutations often have a
mixture of mutated and wild-type mtDNA molecules (het-
eroplasmy). Although there was a positive correlation be-
tween mean age-corrected PTA and urinary heteroplasmy
levels (range 25–66%), this did not reach statistical signifi-
cance (r = 0.37, n = 10, P = 0.3). No relationship was found
between hearing levels and blood heteroplasmy levels
(range 3–30%).
TEOAEs were absent for all patients, except for those
with normal hearing. ABRs were not recordable for the
two patients with profound hearing loss. The mean inter-
peak latencies of ABR waves I-III (2.4ms, range 2.1–2.6),
III-V (1.74ms, range 1.5–1.9) and I-V (4.0ms, range 3.9–
4.4) were within the normal range for the remaining pa-
tients (normal ranges 1.5–2.6ms, 1.3–2.7ms, 3.3–4.7ms,
respectively) (Chalak et al., 2013) (Fig. 1A and B).
PTC analysis was performed for 9/11 patients. Two pa-
tients were unable to complete the test due to the severity
of their hearing impairment. For patients with normal or
mild hearing loss, no tip shifts were detected (mean tip
ratio 1.06, range 1.04–1.14; the tip shift of 1.14 was asso-
ciated with a very broad PTC with an ill-defined tip). For
patients with moderate-to-severe hearing loss, two patients
showed tip shifts at 1 kHz consistent with dead regions (tip
shift ratios 0.79 and 1.11) (Fig. 2A).
POLG patient group
Hearing loss was present for all POLG patients studied
(n = 4/4, mean PTA = 39dB HL, age corrected PTA 14dB
Table 1 Summary of patient demographics and clinical subtypes of the 30 patients enrolled in this study
Disease group Gene Mean age, years (range) M:F Variant
MID
n = 11
MT-TL1 55 (37–75); 2:9 mtDNA m.3243A4G
Polymerase gamma
n = 4
POLG 61 (52–67); 7:3 Compound heterozygous p.Arg467Thr, p.Gly737Arg (n = 3)
Compound heterozygous p.Trp748Ser, p.Gly737Arg (n = 1)
ARHSP
n = 10
SPG7 54 (49–64); 0:4 Compound heterozygous inc. p.Ala510Val (n = 7)
Heterozygous p.Gly349Ser (n = 1)
Heterozygous p.Ala510Val (n = 2)
DOA
n = 5
OPA1 56 (40–68); 3:2 Haploinsufficiency: c.2708_2711del (TTAG), p.V903fsX3
c.2294dupA p.Asn765fsX26 (n = 2)
Missense c.869G4A p.Arg290His (n = 1)
ARHSP = autosomal recessive hereditary spastic paraplegia; DOA = autosomal dominant optic atrophy; MID = maternally inherited deafness and diabetes.
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HL). Moderate high-frequency hearing loss was present in
two patients and one patient had a moderate loss at all
measured frequencies. One patient showed a predominantly
moderate mid-frequency loss (Fig. 1C). TEOAEs were
absent for all patients. ABR latencies were within the
normal range for three patients (mean interpeak latencies
I-III 2.1ms, range 1.6–2.6ms, III-V 1.9ms, range
1.4–2.4ms, I-V 4.2ms, range 4–4.4ms). One patient with
moderate high-frequency loss had delayed wave I-III inter-
peak latencies of 3.15ms and wave I-V latencies of 5.25ms,
but with absent TEOAEs suggestive of primary cochlear
dysfunction. PTC analysis was performed for four patients
and revealed no dead regions (mean tip ratio 1.06, range
1–1.09).
SPG7 patient group
The SPG7 patients (n = 10) either had normal hearing (n = 5/
10) or a moderate high-frequency hearing loss (n = 5/10,
mean PTA = 30dB HL, age corrected PTA 8dB HL).
TEOAEs were present for 9/10 patients. The interpeak laten-
cies of ABR waves I-III (mean latency 2.2ms, range
1.8–2.4ms), III-V (mean 1.84ms, range 1.6–2.2ms) and I-
V (mean 4.0ms, range 3.7–4.5ms) were within the normal
range for all patients. PTC analysis was performed for 9/10
patients. One patient was unable to perform the test due to
ataxia. No dead regions were detected (mean tip ratio 1.02,
range 0.98–1.12; the tip shift of 1.12 was associated with a
broad PTC). See Fig. 2B for a representative PTC.
Figure 2 Psychophysical analysis. (A) Psychophysical tuning curve (PTC) determined using ‘SWPTC’ program showing a significant tip shift
below the signal frequency. Solid line represents raw PTC, dashed line represents the 4-PMA, filled circle indicates the signal frequency (1 kHz) and
the arrow indicates the frequency of the tip of the PTC, estimated from the 4-PMA (790 Hz). (B) PTC analysis in a representative case of
autosomal recessive hereditary spastic paraplegia (ARSHP) showing PTC tip analysed by 4-PMA. The tip of the PTC falls close to the signal
frequency (4 kHz, green circle).
Figure 1 Auditory brain stem responses and pure tone audiograms. (A) Auditory brainstem response (ABR) from the right ear of a
representative m.3243A4G patient showing normal waveform morphology and latencies (wave V marked). The black line represents an average
of individual readings (red lines). (B) Pure tone audiogram showing profound hearing loss at all tested frequencies (representative of hearing in
three patients with m.3243A4G). (C) Pure tone audiogram showing predominantly mid-frequency loss [polymerase gamma (POLG) variant
p.Arg467Thr, p.Gly737Arg].
Letter to the Editor BRAIN 2016: Page 3 of 5 | e3








We also included a cohort of patients with OPA1 muta-
tions harbouring haploinsufficiency (n = 4) or missense
(n = 1) OPA1 mutations. Patients carrying haploinsuffi-
ciency mutations had either normal hearing (n = 3) or a
mild high-frequency loss (n = 2, mean PTA = 31dB HL,
age corrected PTA 5dB HL). TEOAEs were absent for
one patient with high-frequency loss. One patient with a
missense OPA1 mutation had a moderate high-frequency
loss (mean PTA = 51dB HL, age corrected PTA = 21 dB
HL) with absent TEOAEs. The interpeak latencies of
ABR waves I-III (2.1ms, range 1.9–2.2ms), III-V (1.7ms,
range 1.3–1.8ms) and I-V (3.6ms, range 3.4–3.9) were in
the normal range for all patients. PTC analysis was per-
formed for 5/5 patients and did not reveal any dead regions
(mean tip ratio 1.03, range 0.98–1.1).
Discussion
In agreement with previous studies, we found hearing
levels for patients carrying the m.3243A4G mutation
in the range from normal to profound loss, with absent
TEOAEs but preserved ABRs, indicating that the hearing
loss is cochlear in origin (Chinnery et al., 2000).
However, heteroplasmy levels of the m.3243A4G muta-
tion did not account for a significant proportion of the
phenotypic variation (Chinnery et al., 2000; Uimonen et
al., 2001), perhaps because of the limited size of this
study group. For the first time, we show that hearing
loss is also a common feature in POLG disease and simi-
lar to m.3243A4G, this seems to be cochlear in origin.
Likewise, mild cochlear hearing impairment or normal
hearing was found in our SPG7 and OPA1 patient
cohort.
In conclusion, our data suggest that both mtDNA muta-
tions and a range of nuclear-genetic mitochondrial dis-
orders cause hearing loss through cochlear dysfunction.
The presence of dead regions in a small number of patients
carrying the m.3243A4G mutation suggests that mtDNA
point mutations cause specific dysfunction of inner hair
cells. On the other hand, the absence of cochlear dead re-
gions with loss of TEOAEs, but with normal ABRs, suggest
that the hearing loss in patients with POLG, SPG7 and
OPA1 mutations is more likely due to global cochlear dys-
function. Although we cannot exclude the possibility that
severely impaired patients have auditory nerve dysfunction
(masked by the severe cochlear defect), we found no evi-
dence of isolated auditory nerve impairment in our patient
cohort.
Hearing loss has a negative impact on quality of life
and it is often overlooked in patients with mitochondrial
disease who can present with a range of complex hetero-
geneous symptoms. Our data confirm that sensorineural
hearing loss is an important pathological feature in a
range of mitochondrial diseases, including patients with
SPG7 and POLG mutations, who have not been system-
atically studied before. Further improvements in under-
standing the pathogenesis and natural history of
these disorders are important to provide better prognos-
tic information to patients and to inform future trial
design.
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